Exclusive Interview with EMIG released ahead of European Pharmaceutical Pricing & Reimbursement

LONDON - Aug. 5, 2015 - PRLog -- Recent advances in the sophistication of HTA analysis and modelling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.

SMi's 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies with an invaluable insight into the decision making processes and approaches of vital stakeholders.

The two-day conference programme will help further your understanding and enable you to develop best practice approaches to complex market access challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications though case studies presented by GSK, Sanofi, MSD and more who will be presenting at the two-day conference. Unique insight will be provided on:
• Case studies assessing of the impact Biosimilars and Orphan Drugs on the the market with MSD and Quintiles
• Tiered pricing options with a case study from GSK
• Case studies in Reforms with Sanofi sharing their perspective
• Evaluating new models for European reimbursement
• Health Technology Assessment policies
• Changes in UK P&R policy following the UK elections with presentations from industry bodies such as EMIG and the ABPI

When asked about the current PPRS scheme, Leslie Galloway, Chairman, EMIG said:
"We are stuck with this PPRS deal until the end of 2018 and there is no mid term review. The PPRS also fixes QALY thresholds until 2018. The NHS say there is no benefit in this deal for them. Patient Groups say the same and, to say industry is disappointed with the PPRS is an understatement. The rebates should go straight to a New Medicines Fund, as they do in Scotland. The Fund could support the CDF and stimulate the adoption and diffusion of medicines".

To read the full interview with EMIG, download other exclusive content and to view the complete two-day conference programme, visit http://www.smi-online.co.uk/2015europricing1.asp

Speaker Panel includes:
• Leslie Galloway, Chairman, Ethical Medicines Industry Group
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
• Janice Haigh, Practice Leader Market Access, Quintiles
• David Watson, Director of Pricing & Reimbursement, ABPI
• Ken Walsh, Head of Emerging Markets Pricing, GSK
• Toros Sahin, Head of Market Access & Health Economics, Sanofi Turkey
• Alexander Roediger, Director European Union Affairs, MSD
• Leyla Hannbeck, Head of Pharmacy, National Pharmaceutical Association Ltd
• Eric Low, CEO, Myeloma UK
• Maggie Dolan, Regional Pharmacy Procurement Specialist, NHS Commercial Solutions